Recent Analysts’ Ratings Updates for Heartflow (HTFL)

A number of research firms have changed their ratings and price targets for Heartflow (NASDAQ: HTFL):

• 11/13/2025 – Heartflow had its price target raised by analysts at Canaccord Genuity Group Inc. from $39.00 to $40.00. They now have a “buy” rating on the stock.
• 11/13/2025 – Heartflow had its price target raised by analysts at JPMorgan Chase & Co. from $36.00 to $40.00. They now have an “overweight” rating on the stock.
• 11/13/2025 – Heartflow had its price target raised by analysts at Stifel Nicolaus from $35.00 to $40.00. They now have a “buy” rating on the stock.
• 11/1/2025 – Heartflow is now covered by analysts at Weiss Ratings. They set a “sell (d+)” rating on the stock.
• 9/22/2025 – Heartflow had its price target raised by analysts at Canaccord Genuity Group Inc. from $35.00 to $39.00. They now have a “buy” rating on the stock.

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.